Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59

Immunotherapy using MoAbs is inefficient due to limited activation of human effectors by mouse antibodies and multiple protective mechanisms available to host cells against autologous complement. We have used chemically engineered antibody constructs and human complement in vitro to specifically tar...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: HARRIS, C L, KAN, K S, STEVENSON, G T, MORGAN, B P
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Science Inc 1997
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1904584/
https://ncbi.nlm.nih.gov/pubmed/9030877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2249.1997.265-ce1156.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia